Nathanael S Gray

This inventor holds 36 USPTO granted patents and 20 published patent applications, plus 15 CIPO patents and 59 EPO patents, primarily in Kinase Inhibitors. Top assignees: Dana-Farber-Cancer Institute Inc., The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nathanael S Gray. Retrieved from https://idiyas.com/inventor/nathanael-s-gray

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 20)

% Patents Active = 100.0

CIPO Patents = 15 (Patent Applications = 92)

EPO Patents = 59 (Patent Applications = 160)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

32 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

2 out of 3,073

The General Hospital Corporation

patents

1 out of 538

Beth Israel Deaconess Medical Center, Inc.

The Broad Institute, Inc.

patents

6. 1 out of 5,638

The University of Texas System

8. 4 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

IRAK4

EGFR

CDK12

CDK7

SRPK

FAK

HCK

JAK2

AKT

Tead

Protein Degradation

Tyrosine Kinase

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760035 - Covalent EGFR inhibitors and methods of use thereof (2026-10-13),

2. 12753203 - Cyclin-dependent kinase inhibitors and methods of use (2026-10-06),

3. 12747228 - Potent and selective inhibitors of IRAK4 (2026-09-29),

4. 12728132 - INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1), COMBINATIONS AND USES THEREOF (2026-09-08),

5. 12698261 - Cyano-pyrimidine inhibitors of EGFR/HER2 (2026-08-04),

6. 12698259 - Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof (2026-08-04),

7. 12679842 - HCK as a therapeutic target in MYD88 mutated diseases (2026-07-14),

8. 12678508 - Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use (2026-07-14),

9. 12662464 - DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF (2026-06-23),

10. 12653894 - Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use (2026-06-16),

11. 12642857 - Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use (2026-06-02),

12. 12642856 - Degraders of hepatitis C virus NS3/4A protein (2026-06-02),

13. 12637453 - Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof (2026-05-26),

14. 12622909 - Allosteric EGFR inhibitors and methods of use thereof (2026-05-12),

15. 12622901 - Compounds for tau protein degradation (2026-05-12),

Title: Inventor Nathanael S Gray: Pioneering Innovations in Berkeley

Introduction: Nathanael S. Gray is a renowned inventor based in Berkeley, CA, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Nathanael S. Gray holds several patents in the areas of cancer research, precision medicine, and targeted therapies, showcasing his commitment to advancing healthcare through innovation.

Career Highlights: With a distinguished career spanning over two decades, Nathanael S. Gray has held key research positions at leading academic institutions and biotech companies, where he has spearheaded numerous projects that have led to significant advancements in the medical field.

Collaborations: Throughout his career, Nathanael S. Gray has collaborated with top researchers, scientists, and pharmaceutical companies globally, fostering a culture of innovation and knowledge-sharing in the pursuit of developing cutting-edge treatments for complex diseases.

Conclusion: Inventor Nathanael S. Gray's relentless pursuit of innovation and his passion for improving patient outcomes have solidified his reputation as a trailblazer in the field of biotechnology, making him a key figure in shaping the future of healthcare.

Profile summary based on public USPTO records.